HTG Molecular Diagnostics (HTGM) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for HTG Molecular Diagnostics (NASDAQ: HTGM):

  • 2/1/2018 – HTG Molecular Diagnostics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
  • 1/26/2018 – HTG Molecular Diagnostics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
  • 1/25/2018 – HTG Molecular Diagnostics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.25 price target on the stock. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
  • 1/24/2018 – HTG Molecular Diagnostics was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 1/18/2018 – HTG Molecular Diagnostics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
  • 1/17/2018 – HTG Molecular Diagnostics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.00 price target on the stock. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
  • 1/12/2018 – HTG Molecular Diagnostics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
  • 1/10/2018 – HTG Molecular Diagnostics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.75 price target on the stock. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
  • 1/5/2018 – HTG Molecular Diagnostics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
  • 1/5/2018 – HTG Molecular Diagnostics had its price target raised by analysts at Canaccord Genuity to $5.00.
  • 1/5/2018 – HTG Molecular Diagnostics was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 12/27/2017 – HTG Molecular Diagnostics was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

Shares of HTG Molecular Diagnostics Inc (HTGM) opened at $4.48 on Wednesday. The stock has a market capitalization of $62.41 and a P/E ratio of -1.76. HTG Molecular Diagnostics Inc has a 12-month low of $1.20 and a 12-month high of $13.25.

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply